Literature DB >> 20486863

Safety evaluation of zotepine for the treatment of schizophrenia.

Michael Riedel1, Richard Musil, Florian Seemüller, Ilja Spellmann, Hans-Jürgen Möller, Rebecca Schennach-Wolff.   

Abstract

IMPORTANCE OF THE FIELD: Atypical antipsychotics have become the first-line treatment for patients suffering from schizophrenia in the industrialized world. Given the frequent necessity of a life-long enduring antipsychotic treatment, the compounds' safety profile is of great importance for patients and caregivers. Zotepine is an antipsychotic with atypical properties and previous data have suggested a very favorable side effect profile. AREAS COVERED IN THIS REVIEW: The aim of this review is to provide a broad knowledge base on the safety profile of zotepine deriving from currently available research results published in English medical databases. The focus of this research reports starts in the 1990s with zotepine's approval in Europe. WHAT THE READER WILL GAIN: This paper incorporates data on placebo-controlled studies of zotepine as well as studies with comparator compounds also beyond the diagnostic boarder of schizophrenia regarding zotepine's safety. TAKE HOME MESSAGE: The take home message of this safety evaluation of zotepine is that compared to typical compounds zotepine induces less extrapyramidal side effects; however, in terms of comparing zotepine's safety with other atypical antipsychotics more studies are needed to draw final conclusions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486863     DOI: 10.1517/14740338.2010.486787

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  1 in total

1.  Tolerability of zotepine in Indian patients: Preliminary experience.

Authors:  Ram Jeevan Bishnoi; Venu Gopal Jhanwar
Journal:  Ind Psychiatry J       Date:  2010-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.